<DOC>
	<DOCNO>NCT02156895</DOCNO>
	<brief_summary>The objective study monitor usage INLYTA® real practice , include adverse event associate INLYTA® .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Observe Safety Efficacy Inlyta South Korea</brief_title>
	<detailed_description>Investigators choose patient within scope I/E criterion</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients diagnose advanced RCC failure one prior systemic therapy . Any patient agree Pfizer company work behalf Pfizer use his/her information . Patients hypersensitivity axitinib component INLYTA® . Patients 18 . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Korean PMS Axitinib</keyword>
	<keyword>Metastatic RCC ; 2nd line</keyword>
</DOC>